Paper9748116
The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
Frei E and 4 others. Clin Cancer Res, 1998. Cited by 78 papers, by iCite.
Cite this record
ConductScience Library. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Papers, record 9748116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9748116
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Neoplasms | Major topic |
| Clinical Trials as Topic | |
| Dose-Response Relationship, Drug | |
| Humans |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | Background |
Source ClinicalTrials.gov
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41140641 | Stackelberg Evolutionary Games of Cancer Treatment: What Treatment Strategy to Choose if Cancer Can be Stabilized? | Dyn Games Appl | 2025 | https://conductscience.org/library/papers/41140641 | PubMed |
| 37446271 | Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37446271 | PubMed |
| 36221000 | Mitigating acute chemotherapy-associated adverse events in patients with cancer. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/36221000 | PubMed |
| 35440517 | Modulation of Reactive Oxygen Species to Overcome 5-Fluorouracil Resistance. | Biomol Ther (Seoul) | 2022 | https://conductscience.org/library/papers/35440517 | PubMed |
| 35340557 | Management of chemotherapy dose intensity for metastatic colorectal cancer. | Oncol Lett | 2022 | https://conductscience.org/library/papers/35340557 | PubMed |
| 34741706 | In vitro evaluation of the anticancer activity of barbituric/thiobarbituric acid-based chromene derivatives. | Mol Biol Rep | 2021 | https://conductscience.org/library/papers/34741706 | PubMed |
| 31799475 | Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. | Contemp Clin Trials Commun | 2019 | https://conductscience.org/library/papers/31799475 | PubMed |
| 31742555 | A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. | Elife | 2019 | https://conductscience.org/library/papers/31742555 | PubMed |
| 30381824 | Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. | Int J Cancer | 2019 | https://conductscience.org/library/papers/30381824 | PubMed |
| 29114963 | Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. | Cancer Sci | 2018 | https://conductscience.org/library/papers/29114963 | PubMed |
| 28440955 | Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. | Cancer | 2017 | https://conductscience.org/library/papers/28440955 | PubMed |
| 26912903 | Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/26912903 | PubMed |
| 25895611 | Clinical management of breast cancer heterogeneity. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/25895611 | PubMed |
| 25795051 | Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation. | Drug Deliv Transl Res | 2015 | https://conductscience.org/library/papers/25795051 | PubMed |
| 25755993 | Development of oxaliplatin encapsulated in magnetic nanocarriers of pectin as a potential targeted drug delivery for cancer therapy. | Results Pharma Sci | 2012 | https://conductscience.org/library/papers/25755993 | PubMed |
| 24512451 | Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. | J Vet Intern Med | 2014 | https://conductscience.org/library/papers/24512451 | PubMed |
| 24386166 | Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. | PLoS One | 2013 | https://conductscience.org/library/papers/24386166 | PubMed |
| 23682309 | Engineering and Applications of DNA-Grafting Polymer Materials. | Chem Sci | 2013 | https://conductscience.org/library/papers/23682309 | PubMed |
| 23251029 | Defining principles of combination drug mechanisms of action. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23251029 | PubMed |
| 20443090 | Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo. | AAPS PharmSciTech | 2010 | https://conductscience.org/library/papers/20443090 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9748116
GET https://conductscience.org/api/papers/v1/9748116/cited_by?page=2